Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer.
The company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively.
Executive Interviews
Candel Therapeutics secures $130M loan facility to advance clinical pipeline
Executive Interviews
Candel Therapeutics’ CAN-2409 delivers durable benefit in positive phase 3 prostate cancer trial
